The Prognostic Significance of Baseline Serum Ferritin in Patients with Non-Hodgkin Lymphomas: A Prospective Single-Institution Study
EI-Habashy, D., Tawfik, E., Alhassanin, S., Shehata, A., Aldesoky Ahmed, A. (2022). The Prognostic Significance of Baseline Serum Ferritin in Patients with Non-Hodgkin Lymphomas: A Prospective Single-Institution Study. EKB Journal Management System, 89(2), 7411-7418. doi: 10.21608/ejhm.2022.274809
Dina M. EI-Habashy; Eman A. Tawfik; Suzan A. Alhassanin; Amira F. Shehata; Amira I Aldesoky Ahmed. "The Prognostic Significance of Baseline Serum Ferritin in Patients with Non-Hodgkin Lymphomas: A Prospective Single-Institution Study". EKB Journal Management System, 89, 2, 2022, 7411-7418. doi: 10.21608/ejhm.2022.274809
EI-Habashy, D., Tawfik, E., Alhassanin, S., Shehata, A., Aldesoky Ahmed, A. (2022). 'The Prognostic Significance of Baseline Serum Ferritin in Patients with Non-Hodgkin Lymphomas: A Prospective Single-Institution Study', EKB Journal Management System, 89(2), pp. 7411-7418. doi: 10.21608/ejhm.2022.274809
EI-Habashy, D., Tawfik, E., Alhassanin, S., Shehata, A., Aldesoky Ahmed, A. The Prognostic Significance of Baseline Serum Ferritin in Patients with Non-Hodgkin Lymphomas: A Prospective Single-Institution Study. EKB Journal Management System, 2022; 89(2): 7411-7418. doi: 10.21608/ejhm.2022.274809

The Prognostic Significance of Baseline Serum Ferritin in Patients with Non-Hodgkin Lymphomas: A Prospective Single-Institution Study

The Egyptian Journal of Hospital Medicine
Article 195, Volume 89, Issue 2, October 2022, Page 7411-7418  XML PDF (558.46 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2022.274809
View on SCiNiTO View on SCiNiTO
Authors
Dina M. EI-Habashy; Eman A. Tawfik; Suzan A. Alhassanin; Amira F. Shehata; Amira I Aldesoky Ahmed
lecturer of clinical oncology and nuclear medicine at clinical oncology department menofia university hospitals
Abstract
Background: Hyperferritinemia has been linked to a worse prognosis in several types of cancer, and it is often seen in patients with malignancies.
Objectives: The goal of this research was to learn how baseline blood ferritin levels affect prognosis among cases who had non-Hodgkin lymphoma (NHL).
Patients and Methods: From May 2016 to April 2019, from the Menoufia University Clinical Oncology Department we gathered data prospectively. 77 patients with non-Hodgkin lymphoma had their clinicopathological features and serum ferritin levels evaluated. The Kaplan-Meier technique was used to calculate time to treatment failure (TTF) and overall survival (OS).
Results: High serum ferritin levels were significantly associated with advanced stage, poor performance status (PS), high/ high-intermediate international prognostic index (IPI), elevated lactate dehydrogenase (LDH) and elevated β2 microglobulin in NHL (P= 0.023, P= 0.002, P= 0.001, P <0.001and P <0.001 respectively) while hyperferritinemia was significantly associated with advanced stage and elevated β2 microglobulin in HL (P =0.036 and P =0.003 respectively). No statistically significant correlations were detected between baseline ferritin levels; and response to therapy, TTF and OS in NHL patients.
Conclusion: Malignant lymphoma patients whose baseline serum ferritin was high tended to have more advanced illness. However, no association between an increased ferritin level and the outcome of survival analysis was found.
 
Keywords
Serum Ferritin; Non- Hodgkin Lymphomas; Hyperferritinemia
Statistics
Article View: 144
PDF Download: 277